232 related articles for article (PubMed ID: 2725497)
1. The BCR-ABL oncogene transforms Rat-1 cells and cooperates with v-myc.
Lugo TG; Witte ON
Mol Cell Biol; 1989 Mar; 9(3):1263-70. PubMed ID: 2725497
[TBL] [Abstract][Full Text] [Related]
2. Transformation of an interleukin 3-dependent hematopoietic cell line by the chronic myelogenous leukemia-specific P210bcr/abl protein.
Daley GQ; Baltimore D
Proc Natl Acad Sci U S A; 1988 Dec; 85(23):9312-6. PubMed ID: 3143116
[TBL] [Abstract][Full Text] [Related]
3. The CML-specific P210 bcr/abl protein, unlike v-abl, does not transform NIH/3T3 fibroblasts.
Daley GQ; McLaughlin J; Witte ON; Baltimore D
Science; 1987 Jul; 237(4814):532-5. PubMed ID: 2440107
[TBL] [Abstract][Full Text] [Related]
4. Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR/ABL.
Kelliher MA; McLaughlin J; Witte ON; Rosenberg N
Proc Natl Acad Sci U S A; 1990 Sep; 87(17):6649-53. PubMed ID: 2204061
[TBL] [Abstract][Full Text] [Related]
5. In vitro transformation of immature hematopoietic cells by the P210 BCR/ABL oncogene product of the Philadelphia chromosome.
McLaughlin J; Chianese E; Witte ON
Proc Natl Acad Sci U S A; 1987 Sep; 84(18):6558-62. PubMed ID: 3498165
[TBL] [Abstract][Full Text] [Related]
6. Alternative forms of the BCR-ABL oncogene have quantitatively different potencies for stimulation of immature lymphoid cells.
McLaughlin J; Chianese E; Witte ON
Mol Cell Biol; 1989 May; 9(5):1866-74. PubMed ID: 2747638
[TBL] [Abstract][Full Text] [Related]
7. The chronic myelogenous leukemia-specific P210 protein is the product of the bcr/abl hybrid gene.
Ben-Neriah Y; Daley GQ; Mes-Masson AM; Witte ON; Baltimore D
Science; 1986 Jul; 233(4760):212-4. PubMed ID: 3460176
[TBL] [Abstract][Full Text] [Related]
8. Bcr-Abl efficiently induces a myeloproliferative disease and production of excess interleukin-3 and granulocyte-macrophage colony-stimulating factor in mice: a novel model for chronic myelogenous leukemia.
Zhang X; Ren R
Blood; 1998 Nov; 92(10):3829-40. PubMed ID: 9808576
[TBL] [Abstract][Full Text] [Related]
9. Bcr-Abl has a greater intrinsic capacity than v-Abl to induce the neoplastic expansion of myeloid cells.
Gross AW; Ren R
Oncogene; 2000 Dec; 19(54):6286-96. PubMed ID: 11175343
[TBL] [Abstract][Full Text] [Related]
10. The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity.
Li S; Ilaria RL; Million RP; Daley GQ; Van Etten RA
J Exp Med; 1999 May; 189(9):1399-412. PubMed ID: 10224280
[TBL] [Abstract][Full Text] [Related]
11. v-abl causes hematopoietic disease distinct from that caused by bcr-abl.
Scott ML; Van Etten RA; Daley GQ; Baltimore D
Proc Natl Acad Sci U S A; 1991 Aug; 88(15):6506-10. PubMed ID: 1862078
[TBL] [Abstract][Full Text] [Related]
12. Role of p21 RAS in p210 bcr-abl transformation of murine myeloid cells.
Mandanas RA; Leibowitz DS; Gharehbaghi K; Tauchi T; Burgess GS; Miyazawa K; Jayaram HN; Boswell HS
Blood; 1993 Sep; 82(6):1838-47. PubMed ID: 7691239
[TBL] [Abstract][Full Text] [Related]
13. Bcr: a negative regulator of the Bcr-Abl oncoprotein.
Wu Y; Ma G; Lu D; Lin F; Xu HJ; Liu J; Arlinghaus RB
Oncogene; 1999 Aug; 18(31):4416-24. PubMed ID: 10442632
[TBL] [Abstract][Full Text] [Related]
14. BCR/ABL P210 and P190 cause distinct leukemia in transgenic mice.
Voncken JW; Kaartinen V; Pattengale PK; Germeraad WT; Groffen J; Heisterkamp N
Blood; 1995 Dec; 86(12):4603-11. PubMed ID: 8541551
[TBL] [Abstract][Full Text] [Related]
15. The role of c-Myc protooncogene in chronic myelogenous leukemia.
Nieborowska-Skórska M; Ratajczak MZ; Calabretta B; Skórski T
Folia Histochem Cytobiol; 1994; 32(4):231-4. PubMed ID: 7758616
[TBL] [Abstract][Full Text] [Related]
16. BCR first exon sequences specifically activate the BCR/ABL tyrosine kinase oncogene of Philadelphia chromosome-positive human leukemias.
Muller AJ; Young JC; Pendergast AM; Pondel M; Landau NR; Littman DR; Witte ON
Mol Cell Biol; 1991 Apr; 11(4):1785-92. PubMed ID: 2005881
[TBL] [Abstract][Full Text] [Related]
17. bcr/abl and src but not myc and ras replace v-abl in lymphoid transformation.
Engelman A; Rosenberg N
Mol Cell Biol; 1990 Aug; 10(8):4365-9. PubMed ID: 2164639
[TBL] [Abstract][Full Text] [Related]
18. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome.
Daley GQ; Van Etten RA; Baltimore D
Science; 1990 Feb; 247(4944):824-30. PubMed ID: 2406902
[TBL] [Abstract][Full Text] [Related]
19. Effect of herbimycin A, an antagonist of tyrosine kinase, on bcr/abl oncoprotein-associated cell proliferations: abrogative effect on the transformation of murine hematopoietic cells by transfection of a retroviral vector expressing oncoprotein P210bcr/abl and preferential inhibition on Ph1-positive leukemia cell growth.
Okabe M; Uehara Y; Miyagishima T; Itaya T; Tanaka M; Kuni-Eda Y; Kurosawa M; Miyazaki T
Blood; 1992 Sep; 80(5):1330-8. PubMed ID: 1515646
[TBL] [Abstract][Full Text] [Related]
20. The coiled-coil domain and Tyr177 of bcr are required to induce a murine chronic myelogenous leukemia-like disease by bcr/abl.
He Y; Wertheim JA; Xu L; Miller JP; Karnell FG; Choi JK; Ren R; Pear WS
Blood; 2002 Apr; 99(8):2957-68. PubMed ID: 11929787
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
